Key clinical point: Adding pemetrexed to bevacizumab maintenance for advanced nonsquamous non–small cell lung cancer (NSCLC) improves progression-free survival but not overall survival.
Major finding: The median progression-free survival was 5.7 months with pemetrexed-bevacizumab maintenance and 4.0 months with bevacizumab maintenance (hazard ratio, 0.67; P < .001). The median overall survival was 23.3 months and 19.6 months, respectively (HR, 0.87; P = .069).
Study details: A phase 3 trial of 599 patients with previously untreated advanced nonsquamous non–small cell lung cancer.
Disclosures: The study was supported, in part, by Eli Lilly Japan KK. The authors disclosed financial affiliations with Eli Lilly and other companies.
Seto T et al. J Clin Oncol. 2020 Mar 10;38(8):793-803.